For Patients with Schizophrenia Being Treated with Classical Antipsychotic Drugs

For patients with schizophrenia being treated with classical antipsychotic drugs, the real-world rates of relapse are significantly higher than best-case rates because

A) the best-case rates are based on inaccurate assumptions about neurochemistry.
B) many patients stop taking their medication to avoid unpleasant side effects.
C) best-case rates are promoted by pharmaceutical companies trying to market their drugs.
D) classical antipsychotic drugs only work for short periods of time.